Invizyne Technologies Files Form S-1 for $17.2M IPO on Nasdaq

Invizyne Technologies, Inc. has announced the filing of a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for a proposed public offering of its common stock. The offering will consist of 4,300,000 shares of common stock, with a price per share of $4.00, resulting in gross proceeds of $17.2 million. Invizyne has applied to list its common shares on The Nasdaq Stock Market under the ticker symbol IZTC. Public Ventures, LLC will serve as the underwriter and sole book manager for the offering. The preference for the shares will be given to holders of MDB Class A Shares, followed by other beneficial shareholders of MDB and then Invizyne. Individuals who indicate interest through their brokers or dealers will be considered if shares remain available. The registration statement has not yet become effective, and no sales can take place until it does. Interested parties can acquire a copy of the prospectus related to the offering from the SEC website or by contacting Invizyne’s Investor Relations department. Invizyne Technologies, Inc. is a biomanufacturing technology company that specializes in enzyme-based systems. Through its SimplePath™ platform, the company aims to revolutionize biomanufacturing by producing a diverse range of chemicals using renewable resources. The forward-looking statements made in this press release are subject to risks and uncertainties.